Chemours™

Second Quarter 2025 Earnings Presentation

August 6, 2025

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2025, the full year 2025 and the Company’s refreshed corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, any future insurance recoveries,, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the U.S. or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this presentation, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flow, Free Cash Flow Conversion Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.

Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this presentation, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this presentation may be different from the methods used by other companies. The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.

Second Quarter 2025 Highlights

Generated $1.6B in Net Sales and $253M in Adjusted EBITDA

Achieved 65% YoY Net Sales growth for Opteon™ Refrigerants in TSS, reflecting continued strong adoption

Announced a settlement with the State of New Jersey to comprehensively resolve all environmental claims including PFAS statewide

Returned $13M in cash to shareholders in Q2; Q3 dividend approved

Continued strong execution of Chemours' Pathway to Thrive three-year corporate strategy

Second Quarter 2025 Financial Summary

($ in millions unless otherwise noted; excludes per share amounts)

	2Q25	2Q24 [5]	Y-o-Y Δ	1Q25	Q-o-Q Δ
Net Sales	**$1,615**	**$1,554**	**$61**	**$1,368**	**$247**
Net (Loss) / Income [1]	($381)	$60	($441)	($4)	($377)
Adj. Net Income [2]	$87	$58	$29	$19	$68
EPS [3]	**($2.54)**	**$0.39**	**($2.93)**	**($0.03)**	**($2.51)**
Adj. EPS [2,3]	**$0.58**	**$0.38**	**$0.20**	**$0.13**	**$0.45**
Adj. EBITDA [2,4]	**$253**	**$207**	**$46**	**$166**	**$87**
Operating Cash Flow	$93	($620)	$713	($112)	$205
Capex	($43)	($73)	$30	($84)	$41
Free Cash Flow	**$50**	**($693)**	**$743**	**($196)**	**$246**

1. Net (Loss) / Income attributable to The Chemours Company.
2. Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items. Please refer to the attached "GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)" table.
3. Calculation based on diluted share count.
4. Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. Please refer to the attached "GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)" table.
5. As previously disclosed in the first quarter of 2025, certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025.

Adjusted EBITDA Bridge: 2Q25 versus 2Q24

($ in millions)



Price Impacts: $14 million due to higher pricing in TSS primarily driven by stronger Opteon™ Refrigerant blends aftermarket demand and strong pricing in APM, in connection with increased sales into high-value applications as well as solid sales execution for our SPS Capstone™ product line wind down, partially offset by lower pricing globally in TT

Volume Impacts: $34 million primarily driven by increased volumes in TSS's Opteon™ Refrigerant blends, partially offset by decreased volumes in APM

Cost/Other: ($9) million primarily driven by higher input and operational costs in TT, lower fixed cost absorption in APM, and minor input cost increases in TSS, partially offset by lower Corporate Expenses

Currency: $7 million primarily driven by favorable EUR currency in TT

[5] Refer to footnote provided on the preceding slides.

See reconciliation of Non-GAAP measures in the Appendix

Quarterly Segment Summary

($ in millions unless otherwise noted)

Net Sales [5]



Adjusted EBITDA and Margin [5] (%)



[5] Refer to footnote provided on the preceding slides.

Liquidity Position as of June 30, 2025

($ in millions unless otherwise noted)

Total Liquidity [9]	**$1.5B**
Gross Debt	**$4.2B**
Net Debt [10]	**$3.7B**
TTM Net Leverage [11]	**4.7x**



6 Total cash balances include $50 million and $51 million of restricted cash and restricted cash equivalents on Chemours' Balance Sheets as of March 31, 2025 and June 30, 2025, respectively. Restricted cash of $50 million at the end of the first quarter and $51 million at the end of the second quarter includes cash and cash equivalents held in escrow under the terms of the Memorandum of Understanding (MOU) related to potential future legacy liabilities.

7 Cash to shareholders reflects $13 million in dividends paid to shareholders during the second quarter of 2025.

8 Other primarily includes favorable FX impact on cash net of debt repayments.

9 Total liquidity is calculated as the sum of $502 million unrestricted cash and cash equivalents and $954 million of revolving credit capacity, net of outstanding letters of credit. Restricted cash and restricted cash equivalents totaling $51 million is not included in this calculation. The Company announced an amendment and extension to its credit agreement in May 2025. The amended credit facility extends commitments to 2030 with a capacity of up to $1 billion until October 2026, comprised of $780 million maturing on May 2, 2030 and $220 million on October 7, 2026.

10 Net Debt, which we also refer to herein as Total Debt Principal, Net, is calculated as gross debt less unrestricted cash and cash equivalents.

11 TTM Net Leverage reflects Total Debt Principal, Net at quarter-end divided by trailing twelve months of Adjusted EBITDA.

Strategic Progress: Pathway to Thrive

Our Corporate Strategy: "Pathway to Thrive"

Pillars for Success

PATHWAY TO THRIVE

Operational Excellence	Enabling Growth	Portfolio Management	Strengthening the Long Term
❑ Manufacturing excellence as a basis for success ❑ Improved and standardized operating model for consistent execution ❑ Continuous improvement to adapt to changing markets	❑ Investing smartly in selected growth projects ❑ Commercial effectiveness to drive sales growth ❑ Innovation and new product development	❑ Holistic portfolio analysis focused on distinct value creation metrics ❑ Shift product mix to higher value applications in growing end markets ❑ Optimize asset footprint	❑ Measurable progress on resolving legacy liabilities in the interest of stakeholders ❑ Responsible manufacturing practices ❑ Targeted policy efforts
>$250M cost reduction from 2024 to 2027	>5% Sales CAGR from 2024 to 2027	Driving shareholder value	Recognizing criticality of our chemistries

Balanced & Disciplined Capital Allocation To Create Shareholder Value

Our Corporate Strategy: "Pathway to Thrive"

Progress Achieved to Date

PATHWAY TO THRIVE

Operational Excellence	Enabling Growth	Portfolio Management	Strengthening the Long Term
✓ Notable progress against the $125M of run-rate savings by end of 2025 across all areas of the company ✓ Corpus Christi, TX capacity expansion to support low GWP regulatory transitions ahead of planned ramp ✓ Established new manufacturing & capital Center of Excellence (COE) to drive improved performance and spend diligence ✓ Announced Matthew Conti as new Chief Human Resources Officer (CHRO)	✓ 65% YoY growth in Opteon™ Refrigerants, with advantaged market position to secure aftermarket share ✓ Announced new leader for TSS's Liquid Cooling venture, paired with an announced strategic collaboration agreement with DataVolt to demonstrate & develop advanced liquid cooling solutions for data centers ✓ Advanced TiO_2 share gains in western markets* meeting customer demand, while experiencing business interruption	✓ Progressed APM European asset review through announced exit of SPS Capstone™ business, to prioritize higher return businesses and strengthen Chemours' overall portfolio ✓ Continued shift of product mix to higher value applications with a sequential increase in APM Performance Solutions with a sequential increase of ~14% in Q2	✓ Agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all environmental claims, including PFAS statewide ✓ Agreed to settlement agreement with Hoosick Falls, NY ✓ Drove advocacy for the importance of Chemours' essential chemistry as a part of recent U.S. trade policy changes and evolving EU regulatory landscape ✓ U.S. Dept. of Defense recent report confirming PFAS-based applications are critical to U.S. national security

Balanced & Disciplined Capital Allocation To Create Shareholder Value

*Primarily includes North America, Europe and Brazil.

Strengthening the Long-Term: Resolving Legacy Liabilities

Announced a Settlement with the State of New Jersey to Comprehensively Resolve Environmental Claims Including PFAS

Key Considerations

- Resolves all environmental claims, including those related to PFAS, across four current and former operating sites (Chambers Works, Parlin, Pompton Lakes and Repauno) and all statewide PFAS claims
- Chemours' discounted share of settlement payments is ~$250 million, reflecting a 25-year payment time frame, excluding insurance recoveries
- 2025 Insurance proceeds MOU between companies provides $150* million to Chemours to be used to fund NJ settlement payments
- No out-of-pocket NJ settlement payments for Chemours expected through at least 2030 from combination of insurance proceeds (~$150* million) and existing escrow funds (~$50* million)
- The present value of payments remaining after 2030 by Chemours for the New Jersey settlement is approximately $80 million
- $16.5* million allocated to resolve AFFF/PFAS litigation unrelated to existing sites
- Continues cooperation between Companies to resolve legacy litigation matters under the framework of existing 2021 MOU cost sharing arrangement

*Amounts are presented on an undiscounted basis. Over the first 5 years, Chemours is obligated to fund $200 million of gross settlement payments, of which $150 million will be funded by the insurance proceeds MOU and we expect the remaining $50 million to be funded from existing restricted cash held by Chemours.

Strengthening the Long-Term: Resolving Legacy Liabilities

Continued Progress

2017:
1st Ohio MDL Settlement ($670.7M)

February 2019:
Consent Order with NCDEQ for Fayetteville Works

January 2021:
MOU with Corteva, EID, DuPont and Chemours on PFAS Liabilities: Created $4B cost sharing arrangement

2nd Ohio MDL Settlement ($83M)

July 2021:
Delaware NRD Settlement ($50M + $25M supplement)

June 2023:
U.S. Public Water System Class Action Settlement ($1.185B) Reached

Note: Finalized in Q2 2024

November 2023:
Ohio NRD Settlement Reached ($110M)

December 2024:
3rd Ohio MDL Settlement with Closure of MDL ($58.5M)

July/August 2025:
Hoosick Falls Settlement ($27M)
NJ Settlement (~$500M NPV)
Insurance Proceeds MOU

Qualified Spend Totaling ~$2.6B to Date under the 2021 MOU

- **NJ settlement captured on an NPV basis under the 2021 MOU cost sharing arrangement**
- **Qualified spend to date does not currently reflect anticipated insurance proceeds to be applied against the settlement; total potential insurance proceeds, to the three companies, to be recovered from the noticed policy limits of up to $750 million**

Priorities for Resolving Remaining Legacy Matters

1. Opt out water system claims that involve costs to abate or meet regulatory requirements
2. Governmental-related claims, including regulatory agencies and State AGs (may arise in both regulatory process and litigation proceedings (state NRD matters))
3. Personal injury claims
4. Property-related claims, primarily involving loss of value

Q3 and Full Year Guidance

Third Quarter 2025 Guidance

Sequential Business Outlook:

- **<u>Consolidated</u>**
  - <u>Net Sales:</u> Expected to decrease 4-6% sequentially
  - <u>Adjusted EBITDA:</u> Expected to range between $175 million and $195 million
  - <u>Corporate Expenses</u> as an offset to Adjusted EBITDA: Expected to decrease approximately 5% sequentially
  - <u>Capital Expenditures:</u> Approximately $50 million
  - <u>Free Cash Flow Conversion:</u> Expected to range 60-80%
- **<u>TSS</u>**
  - <u>Net Sales:</u> Expected to decrease in the mid single-digits (%) sequentially, driven by overall traditional refrigerant seasonality concentrated in Freon™ Refrigerants
  - <u>Adjusted EBITDA:</u> Expected to decrease in the low teens (%) sequentially, primarily driven by the referenced seasonality as well as overall product mix
- **<u>TT</u>**
  - <u>Net Sales:</u> Expected to decrease by low single-digits (%) sequentially, driven by seasonality and regional sales mix, with volumes expected to remain stable
  - <u>Adjusted EBITDA:</u> Expected to decrease in the low-teens (%) sequentially due to lower sales paired with certain operational disruptions. Costs associated with these operational issues are anticipated to approximate $15 million in the third quarter
- **<u>APM</u>**
  - <u>Net Sales:</u> Expected to decrease in the mid-teens (%) sequentially due to production constraints associated with an outage at our Washington Works site in the U.S.
  - <u>Adjusted EBITDA:</u> Expected to approximate $15 million in the third quarter, considering lower sales as well as additional costs from the referenced site outage, which are anticipated to approximate $20 million

3Q25 Net Sales and Adjusted EBITDA Outlook





Full Year 2025 Outlook[12]

Net Sales	$5.9B - $6.0B
Adjusted EBITDA	$775M - $825M
CapEx	~$250M

Free Cash Flow

Free Cash Flow conversion expected to be solidly positive for FY25, with Free Cash Flow conversion in 2H 2025 expected to be in the range of 60% to 80%

- Consistent with business seasonality, anticipate working capital unwind
- Capital spend focused on critical areas, with spend concentrated later in 2025

Key Business Factors and Assumptions

- High end of Adjusted EBITDA range anticipates an improving demand environment for TT and TSS, paired with operational impacts from the Q3 outage to APM being more limited than expected
- Low end of Adjusted EBITDA range anticipates a weaker demand environment for TT and TSS, with operational impacts from the Q3 outage for APM being more impactful than originally expected
- Annual guidance contemplates Q3 operational disruptions in TT and outage impacts in APM of $35 million, collectively, to be resolved in the 4th quarter
- Net leverage ratio is anticipated to improve throughout 2025

Capital Allocation Approach

- Continue to provide shareholder returns through dividends reflecting balanced and disciplined capital allocation policy under Pathway to Thrive
- Enables balance sheet flexibility to drive long-term shareholder value
- Declared quarterly cash dividend for Q3 of $0.0875 per share

[12] For information on our outlooked non-GAAP measures, please refer to the attached "2025 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income, Estimated Adjusted EBITDA" table.

See reconciliation of Non-GAAP measures in the Appendix

Appendix

TSS Segment Net Sales and Adjusted EBITDA (Unaudited)[5]

($ in millions)
% of total Net Sales



($ in millions)



Net Sales: The 11% year-over-year volume increase was driven by stronger demand for Opteon™ Refrigerant blends in connection with the stationary air conditioning (AC) transition under the U.S. AIM Act, partially offset by lower volumes for Freon™ Refrigerant products under this regulatory transition. The 4% year-over-year increase in pricing was primarily attributed to stronger Opteon™ Refrigerant aftermarket demand.

Adjusted EBITDA: The increase was primarily driven by volume and price increases due to increased demand for Opteon™ Refrigerant blends products in connection with the stationary AC regulatory transition as referenced above, partially offset by minor input cost increases.

[5] Refer to footnote provided on the preceding slides.

TT Segment Net Sales and Adjusted EBITDA (Unaudited)[5]

($ in millions)



($ in millions)



Net Sales: The year-over-year decrease was primarily driven by a 4% decrease in price globally, partially offset by favorable currency movements adding a slight 1% tailwind. Volumes remained generally flat overall, with stronger demand in North America and Europe offsetting lower volumes in other non-western markets.

Adjusted EBITDA: The decline was primarily driven by the decrease in price, partially offset by favorable currency movements. The TT operations were disrupted by a now resolved external rail line service interruption impacting feedstock mix and a gap in operational discipline in a low demand environment. As a result of improved agility under its manufacturing COE, these disruptions did not impact the Company's ability to supply its customers. However, in order to fulfill customer orders, due to this rail line disruption, the Company elected to consume higher-cost ore feedstock, which resulted in incremental costs of $15 million in the second quarter. The net costs associated with other operational disruptions were $8 million for the quarter.

[5] Refer to footnote provided on the preceding slides.

APM Segment Net Sales and Adjusted EBITDA (Unaudited)[5]

($ in millions)
% of total Net Sales



($ in millions)



Net Sales: The 6% year-over-year increase in price was primarily driven by increased sales into high-value applications as well as pricing opportunities associated with the SPS Capstone™ product exit. This was offset by a 6% year-over-year decrease in volume primarily driven by weakness in cyclical end markets impacting Advanced Materials and products serving hydrogen markets under Performance Solutions. Currency impact remained flat.

Adjusted EBITDA: The increase was primarily due to the increase in price as referenced above, partially offset by lower fixed cost absorption due to lower overall volumes.

[5] Refer to footnote provided on the preceding slides.

Segment Net Sales (Unaudited)[5]

($ in millions)	2022				2023				2024				2025	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Net sales by product group and segment														
Opteon™ refrigerants	$ 143	$ 182	$ 150	$ 122	$ 195	$ 200	$ 170	$ 145	$ 200	$ 227	$ 205	$ 178	$ 279	$ 375
Freon™ refrigerants	197	241	177	135	185	226	170	141	173	173	146	124	97	123
Foam, propellants, and other	91	101	98	65	114	107	104	94	81	119	117	88	90	99
Total Thermal & Specialized Solutions	431	524	425	322	494	533	444	380	454	519	468	390	466	597
Titanium dioxide and other minerals	928	968	877	606	632	707	690	651	591	677	672	632	597	657
Total Titanium Technologies	928	968	877	606	632	707	690	651	591	677	672	632	597	657
Advanced materials	268	284	322	266	249	254	220	192	190	212	214	191	178	214
Performance solutions	120	120	133	120	144	140	129	134	113	133	140	133	116	132
Total Advanced Performance Materials	388	404	455	386	393	394	349	326	303	345	354	324	294	346
Performance chemicals and intermediates	26	28	33	30	30	26	18	11	14	13	14	13	11	15
Total Other Non-Reportable Segment	26	28	33	30	30	26	18	11	14	13	14	13	11	15
Total net sales	$ 1,773	$ 1,924	$ 1,790	$ 1,344	$ 1,549	$ 1,660	$ 1,501	$ 1,368	$ 1,362	$ 1,554	$ 1,508	$ 1,359	$ 1,368	$ 1,615

[5] Refer to footnote provided on the preceding slides.

Segment Net Sales by Region (Unaudited)[5]

	2023				2024				2025	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Net sales by geographic region										
North America:										
Thermal & Specialized Solutions	$ 292	$ 319	$ 258	$ 207	$ 271	$ 308	$ 256	$ 194	$ 233	$ 336
Titanium Technologies	262	277	273	242	246	274	270	236	267	282
Advanced Performance Materials	156	150	131	119	124	133	130	112	111	125
Other Non-Reportable Segment	22	17	11	9	9	10	9	7	8	10
Total North America	732	763	673	577	650	725	665	549	619	753
Asia Pacific:										
Thermal & Specialized Solutions	53	56	42	41	39	53	55	53	53	59
Titanium Technologies	147	180	186	191	147	178	171	161	105	125
Advanced Performance Materials	147	145	133	129	105	127	138	148	115	147
Other Non-Reportable Segment	2	4	3	3	3	2	3	3	2	3
Total Asia Pacific	349	385	364	364	294	360	367	365	275	334
Europe, the Middle East, and Africa:										
Thermal & Specialized Solutions	100	106	85	78	92	103	98	69	98	112
Titanium Technologies	133	147	123	116	124	130	126	131	142	156
Advanced Performance Materials	76	85	70	66	63	72	70	53	56	60
Other Non-Reportable Segment	5	4	3	—	2	1	2	2	1	2
Total Europe, the Middle East, and Africa	314	342	281	260	281	306	296	255	297	330
Latin America:										
Thermal & Specialized Solutions	49	52	59	54	52	55	59	74	82	90
Titanium Technologies	90	103	108	102	74	95	105	104	83	94
Advanced Performance Materials	14	14	15	11	11	13	16	11	12	14
Other Non-Reportable Segment	1	1	1	—	—	—	—	1	—	—
Total Latin America	154	170	183	167	137	163	180	190	177	198
Total net sales	$ 1,549	$ 1,660	$ 1,501	$ 1,368	$ 1,362	$ 1,554	$ 1,508	$ 1,359	$ 1,368	$ 1,615

[5] Refer to footnote provided on the preceding slides.

Actual and Projected Disruption & Investment Costs (Unaudited)

	2024					2025			
($, millions)	Q1 - Act	Q2 - Act	Q3 - Act	Q4 - Act	Total	Q1 - Act	Q2 - Act	Q3 - Guide	Total
Disruption Costs									
Thermal & Specialized Solutions (TSS)									
Winter Storm	$ -	$ -	$ -	$ -	$ -	$ 5	$ -	$ -	$ 5
Titanium Technologies (TT)									
Impacts from Altamira Outage	-	8	18	-	26	-	-	-	-
Winter Storm Impact	-	-	-	-	-	7	-	-	7
Rail Impact to Ore Mix	-	-	-	-	-	-	15		15
Operational Disruption	-	-	-	-	-	-	8	15	23
Total TT	-	8	18	-	26	7	23	15	45
Advanced Performance Materials (APM)									
Higher Deferred Maintenance Costs	-	-	-	-	-	5	-	-	5
Outage Costs & Related Impacts	-	-	-	-	-	-	-	20	20
Total APM	-	-	-	-	-	5	-	20	25
Corporate Expenses									
Internal Review Costs	12	11	2	2	27	3	1	2	6
Unallocated Costs *(Applied in consolidation only)*									
TT Transformation Plan	-	11	3	2	16	1	-	-	1
Other Transformation Costs	-	-	-	-	-	-	2	4	6
Total Unallocated	-	11	3	2	16	1	2	4	7
Total Costs	**$ 12**	**$ 30**	**$ 23**	**$ 4**	**$ 69**	**$ 21**	**$ 26**	**$ 41**	**$ 88**
Investment Costs									
TSS - Liquid Cooling & Next Generation Refrigerants	$ 5	$ 4	$ 5	$ 4	**$ 18**	$ 5	$ 5	$ 5	**$ 15**

Segment Net Sales and Adjusted EBITDA (Unaudited)[5]

($ in millions)	2022				2023				2024				2025	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Segment Net Sales														
Thermal & Specialized Solutions	$ 431	$ 524	$ 425	$ 322	$ 494	$ 533	$ 444	$ 380	$ 454	$ 519	$ 468	$ 390	$ 466	$ 597
Titanium Technologies	928	968	877	606	632	707	690	651	591	677	672	632	597	657
Advanced Performance Materials	388	404	455	386	393	394	349	326	303	345	354	324	294	346
Other Non-Reportable Segment	26	28	33	30	30	26	18	11	14	13	14	13	11	15
Total Company Net Sales	$ 1,773	$ 1,924	$ 1,790	$ 1,344	$ 1,549	$ 1,660	$ 1,501	$ 1,368	$ 1,362	$ 1,554	$ 1,508	$ 1,359	$ 1,368	$ 1,615
Segment Adjusted EBITDA														
Thermal & Specialized Solutions	$ 174	$ 213	$ 162	$ 54	$ 185	$ 214	$ 162	$ 124	$ 150	$ 160	$ 139	$ 122	$ 141	$ 207
Titanium Technologies	206	216	137	42	70	87	69	64	69	83	78	70	50	47
Advanced Performance Materials	88	107	112	61	84	81	68	40	30	45	38	47	32	50
Other Non-Reportable Segment	-	(2)	3	1	10	5	2	-	2	3	3	-	1	4
Corporate Expenses	(65)	(59)	(51)	(38)	(45)	(63)	(54)	(50)	(55)	(77)	(54)	(69)	(57)	(53)
Segment Adjusted EBITDA Margin														
Thermal & Specialized Solutions	40%	41%	38%	17%	37%	40%	36%	33%	33%	31%	30%	31%	30%	35%
Titanium Technologies	22%	22%	16%	7%	11%	12%	10%	10%	12%	12%	12%	11%	8%	7%
Advanced Performance Materials	23%	26%	25%	16%	21%	21%	20%	12%	10%	13%	11%	15%	11%	14%
Other Non-Reportable Segment	0%	(7%)	9%	3%	33%	19%	13%	0%	14%	23%	21%	0%	9%	27%

[5] Refer to footnote provided on the preceding slides.

GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio[5] (Page 1/2)

($ in millions except per share amounts)	Three Months Ended June 30, 2025 $ amounts	Three Months Ended June 30, 2025 $ per share*	Three Months Ended June 30, 2024 $ amounts	Three Months Ended June 30, 2024 $ per share*	Three Months Ended March 31, 2025 $ amounts	Three Months Ended March 31, 2025 $ per share*	Twelve Months Ended June 30, 2025 $ amounts	Twelve Months Ended June 30, 2024 $ amounts
(Loss) income before income taxes	$ (261)		$ 69		$ —		$ (292)	$ 79
Net (loss) income attributable to Chemours	$ (381)	$ (2.54)	$ 60	$ 0.39	$ (4)	$ (0.03)	$ (427)	$ 106
Non-operating pension and other post-retirement benefit income	(2)	(0.01)	(2)	(0.01)	(2)	(0.01)	(5)	(3)
Exchange losses, net	4	0.03	7	0.05	3	0.02	10	32
Restructuring, asset-related, and other charges	18	0.12	3	0.02	32	0.21	100	145
Goodwill impairment charge	—	—	—	—	—	—	56	—
Loss on extinguishment of debt	—	—	—	—	—	—	1	1
Gain on sales of assets and businesses, net	—	—	—	—	(1)	(0.01)	(1)	(113)
Transaction costs	2	0.01	—	—	—	—	4	16
Qualified spend recovery	(13)	(0.09)	(8)	(0.05)	(9)	(0.06)	(33)	(37)
Litigation-related charges	299	1.99	(1)	(0.01)	—	—	302	112
Environmental charges	60	0.40	—	—	—	—	75	8
Adjustments made to income taxes	171	1.14	(4)	(0.03)	—	—	178	(17)
(Benefit from) provision for income taxes relating to reconciling items	(71)	(0.47)	3	0.02	—	—	(83)	(38)
Adjusted Net Income	$ 87	$ 0.58	$ 58	$ 0.38	$ 19	$ 0.13	$ 177	$ 212
Net income attributable to non-controlling interests	1		—		—		1	—
Interest expense, net	67		66		66		268	247
Depreciation and amortization	79		74		77		304	297
All remaining provision for income taxes	19		9		4		39	28
Adjusted EBITDA	$ 253		$ 207		$ 166		$ 789	$ 784

[5] Refer to footnote provided on the preceding slides.

GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio[5] (Page 2/2)

($ in millions except per share amounts)	Three Months Ended June 30,				Three Months Ended March 31,		Twelve Months Ended June 30,	
	2025		2024		2025		2025	2024
	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ amounts
Adjusted EBITDA	$ 253		$ 207		$ 166		$ 789	$ 784
Total debt principal							$ 4,177	$ 4,028
Less: Cash and cash equivalents							(502)	(604)
Total debt principal, net							$ 3,675	$ 3,424
Net Leverage Ratio (calculated using GAAP earnings)							(12.6)x	43.3x
Net Leverage Ratio (calculated using Non-GAAP earnings)							4.7x	4.4x
Weighted-average number of common shares outstanding - basic	150,238,691		149,413,167		149,918,386			
Weighted-average number of common shares outstanding - diluted	150,506,761		150,123,060		150,409,580			
Basic (loss) earnings per share of common stock (2)	$ (2.54)		$ 0.40		$ (0.03)			
Diluted (loss) earnings per share of common stock (1) (2)	$ (2.54)		$ 0.39		$ (0.03)			
Adjusted basic earnings per share of common stock (2)	$ 0.58		$ 0.39		$ 0.13			
Adjusted diluted earnings per share of common stock (1) (2)	$ 0.58		$ 0.38		$ 0.13			

(1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended June 30, 2025 and March 31, 2025. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended June 30, 2025 and March 31, 2025 as Adjusted Net Income was in a net income position.

(2) Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers.

* Note: $ per share columns may not sum due to rounding.

[5] Refer to footnote provided on the preceding slides.

GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation

($ in millions)	Three Months Ended			Six Months Ended	
	June 30,		March 31,	June 30,	
	2025	2024	2025	2025	2024
Cash flows provided by (used for) operating activities (1)	$ 93	$ (620)	$ (112)	$ (19)	$ (910)
Less: Purchases of property, plant, and equipment	(43)	(73)	(84)	(127)	(175)
Free Cash Flows	$ 50	$ (693)	$ (196)	$ (146)	$ (1,085)
Adjusted EBITDA	253	207	166	419	398
Free Cash Flow Conversion	20%	(335)%	(118)%	(35)%	(273)%

(1) For the six months ended June 30, 2024, operating cash outflows includes the release of the $606 million of cash and cash equivalents deposited in the qualified settlement fund per the terms of the U.S. public water system settlement agreement.

2025 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income, Estimated Adjusted EBITDA(*)

(In millions except per share amounts)	(Estimated) Year Ending December 31, 2025	
	Low	High
Net loss attributable to Chemours	$ (336)	$ (300)
Restructuring, transaction, and other costs, net (1)	492	492
Adjusted Net Income	156	192
Interest expense, net	272	272
Depreciation and amortization	313	313
All remaining provision for income taxes	34	48
Adjusted EBITDA	$ 775	$ 825

(1) Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.

(*) The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these current estimates.

Chemours™